RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is associated with elevated circulating levels of the chemokine RANTES and with decreased plasma levels of the incretin hormone glucagon-like peptide 1 (GLP-1). GLP-1 is a peptide secreted from intestinal L-cells upon nutrient ingestion. It enhances insulin secretion from pancreatic β-cells and protects from β-cell loss but also promotes satiety and weight loss. In search of chemokines that may reduce GLP-1 secretion we identified RANTES and show that it reduces glucose-stimulated GLP-1 secretion in the human enteroendocrine cell line NCI-H716, blocked by the antagonist Met-RANTES, and in vivo in mice. RANTES exposure to mouse intestinal tissues lowers transport function of the intestinal glucose transporter SGLT1, and administration in mice reduces plasma GLP-1 and GLP-2 levels after an oral glucose load and thereby impairs insulin secretion. These data show that RANTES is involved in altered secretion of glucagon-like peptide hormones most probably acting through SGLT1, and our study identifies the RANTES-receptor CCR1 as a potential target in diabetes therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 1×
“While RANTES levels are elevated in human type 1 and type 2 diabetes (33, 34), GLP-1 concentrations are reduced (31, 46), but no interaction between the two proteins has been described.”
BackgroundGut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.
Jang, H.-J., Kokrashvili, Z., Theodorakis, M. J., Carlson, O. D., Kim, B.-J., Zhou, J., Kim, H. H., Xu, X., Chan, S. L., Juhaszova, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706890104 · Cited by 995 · cited 1×
“Cells were then incubated with or without 500 mM glucose (22) and RANTES in PBS, 1 mM CaCl2, pH 7.”
MethodNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · cited 1×
“The incretin hormone glucagon-like peptide 1 (GLP-1), which is secreted by enteroendocrine L-cells in response to glucose (36) and other nutrients (10, 47, 48), potentiates glucose-stimulated insulin secretion (32), enhances -cell growth and survival, inhibits glucagon release, delays gastric emptying, and suppresses…”
BackgroundGorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo
Cheeseman, C. I. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.273.6.r1965 · Cited by 267
Moriya, R., Shirakura, T., Ito, J., Mashiko, S., & Seo, T. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00412.2009 · Cited by 156 · cited 2×
“The intestinal sodium-dependent glucose transporter SGLT1 has been demonstrated to be pivotal for glucose-induced GLP-1 secretion (20, 29, 40).”
Background
Cited by
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialInflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“RANTES, a proinflammatory chemokine, was demonstrated to reduce glucosedependent secretion of GLP-1 and GLP-2, thereby impairing glucose-induced insulin secretion in mice (112).”
BackgroundSelf-citationShen, L., Chen, Y., Cheng, J., Yuan, S., Zhou, S., Yan, W., Liu, J., Luo, A., & Wang, S. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28819 · Cited by 44
GPR75: an exciting new target in metabolic syndrome and related disorders
Murtaza, B., Asghar, F., & Patoli, D. (2022) · Biochimie · doi:10.1016/j.biochi.2022.01.005 · Cited by 18
Metadata
- Authors
- Pais, R., Zietek, T., Hauner, H., Daniel, H., & Skurk, T.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2014-08-01
- Volume
- 307
- Issue
- 3
- Pages
- G330-G337
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2168920047
- Cited by
- 26
- References
- 6
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. https://app.cochat.ai/papers/10.1152/ajpgi.00329.2013
- The paper
- Pais, R., Zietek, T., Hauner, H., Daniel, H., & Skurk, T. (2014). RANTES (CCL5) reduces glucose-dependent secretion of glucagon-like peptides 1 and 2 and impairs glucose-induced insulin secretion in mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00329.2013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.